Table 1.
Clinical and demographics characteristics of renal transplant patients (n = 27) with TTV sequencing.
| Characteristics | Renal Transplant Patients (n = 27) |
|---|---|
| Age, years old [mean ± SD] | 49.4 ± 13.9 |
| Gender (female) [n (%)] | 14 (51.8) |
| Number of kidney transplantation [n (%)] | |
| First | 22 (81.5) |
| Second | 4 (14.8) |
| Third | 1 (3.7) |
| Cause of end-stage renal disease [n (%)] | |
| Diabetes mellitus | 5 (18.5)) |
| Glomerular disease | 7 (25.9) |
| Hypertensive kidney disease | 2 (7.4) |
| Polycystic kidney disease | 2 (7.4) |
| Other specified disorders of the kidney and ureter | 2 (7.4) |
| Unspecified chronic renal failure | 9 (33.3) |
| CMV serostatus [n (%)] | |
| D+/R+ | 22 (81.5) |
| D−/R+ | 2 (7.4) |
| D+/R− | 3 (11.1) |
| D−/R− | - |
| Pre-transplant renal replacement therapy [n (%)] | |
| Hemodialysis | 23 (85.2) |
| Time on dialysis, months [median (IQR)] | 30.6 (16.3–53.2) |
| Donor age, years old [mean ± SD] | 43.5 ± 20.2 |
| Donor gender (male) [n (%)] | 17 (63.0) |
| Type of donor [n (%)] | |
| Deceased donor | 20 (74.1) |
| Living donor | 7 (25.9) |
| Number of HLA mismatches [median (IQR)] | 5 (4–5) |
| Induction therapy [n (%)] | |
| Thymoglobulin | 26 (96.3) |
| Basiliximab | 1 (3.7) |
| Initial maintenance immunosuppression scheme [n (%)] | |
| Tacrolimus, mycophenolic acid and steroids | 27 (100) |
SD: standard deviation; IQR: interquartile range; D: donor R: recipient.